Cure My Disease

Don't miss your cure!

 Log in / Sign up

A One-Two punch for long COVID? supplement and therapy put to the test

NCT ID NCT05703074

Disease control Sponsor: University Hospital, Akershus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial tests two potential approaches for long COVID: a dietary supplement called nicotinamide riboside (NR) and a mind-body reprocessing therapy (MBRT). The study includes 310 adults aged 18-70 with long COVID symptoms that interfere with daily life. Participants are randomly assigned to receive NR or placebo, and MBRT or usual care, for three months. The goal is to see if these interventions improve health-related quality of life, with follow-up over a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nicotinamide riboside (NR) dietary supplement and mind-body reprocessing therapy (MBRT)
What this could lead to
If successful, this could point toward effective treatments for long COVID, improving quality of life for millions.
What could go wrong
This is a phase 2 trial, so results are preliminary. The supplement and therapy may not outperform placebo or usual care, and side effects or lack of adherence could limit benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

310 people

The number who actually took part.

Started

Jan 2023

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Undergone acute COVID-19, confirmed EITHER by a positive PCR-test OR a positive self-test combined with confirmatory antibody-pattern in blood. * Persistent symptoms at least 6 months following acute COVID-19 without symptom-free interval. * Functional disability to an extent that impacts negatively on normal activities (such as work attendance, physical exercise, social activities, etc.) * Informed consent Exclusion Criteria: * Other chronic illnesses, demanding life situations or concomitant drug use/substance abuse that is considered a plausible cause of persistent symptoms and associated disability * Sustained organ damage (lung, heart, brain) following acute, serious Covid-19 * Pregnancy. * Bedridden * Insufficient command of Norwegian

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID

Contacts and locations

Locations

  • Akershus University Hospital

    Lørenskog, 1478, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.